Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vext ScienceFRA:VV5 67 ROC (Joel Greenblatt) % is 2.13% as of Mar. 2026, which is 88% below its 10-year median of 17.72. GuruFocus rates FRA:VV5 with a GF Score™ of 67/100 and a GF Value™ of €0.94. The stock has 3 warning signs investors should review. Among 982 Drug Manufacturers companies, Vext Science ranks worse than 79.84% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Vext Science's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.13%.
The historical rank and industry rank for Vext Science's ROC (Joel Greenblatt) % or its related term are showing as below:
FRA:VV5'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -38.88 Med: 17.72 Max: 48.4
Current: -19.36
During the past 9 years, Vext Science's highest ROC (Joel Greenblatt) % was 48.40%. The lowest was -38.88%. And the median was 17.72%.
FRA:VV5's ROC (Joel Greenblatt) % is ranked worse than 79.84% of 982
companies
in the Drug Manufacturers industry
Industry Median: 11.405
vs FRA:VV5: -19.36
Vext Science's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Vext Science ROC (Joel Greenblatt) % Related Terms
Vext Science ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Vext Science's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VV5 vs ZTS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vext Science's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vext Science ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vext Science's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Vext Science's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 2.13% mean?
Vext Science (FRA:VV5) has a ROC (Joel Greenblatt) % of 2.13% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Vext Science and its competitors. This is 88% below median its historical median of 17.72. According to the industry distribution chart, Vext Science ranks #784 out of 982 companies in the Drug Manufacturers industry, placing it in the top 79.8%.
Is Vext Science's ROC (Joel Greenblatt) % too high?
Vext Science's current ROC (Joel Greenblatt) % of 2.13% is 88% below median its 10-year median of 17.72. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.41. Vext Science's value of 2.13% is 81.3% below this industry median. Based on the distribution chart, Vext Science ranks #784 out of 982 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vext Science has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Vext Science's ROC (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vext Science ranks #784 out of 982 companies for ROC (Joel Greenblatt) %. This places Vext Science in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 11.41. Vext Science's value of 2.13% is 81.3% below this benchmark. While the company's 10-year median is 17.72 vs. the industry median of 11.41, Vext Science has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.41, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vext Science's current ROC (Joel Greenblatt) % of 2.13% is 81.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Vext Science and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vext Science's current ROC (Joel Greenblatt) % is 2.13%, which is 88% below median its own 10-year median of 17.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vext Science stock overvalued right now?
Vext Science (FRA:VV5) has a current ROC (Joel Greenblatt) % of 2.13%. The stock's GF Value™ is €0.94, compared to a current price of €0.14 — trading 84.8% below its estimated fair value. The current ROC (Joel Greenblatt) % is 2.13%, which is 88% below median its 10-year median of 17.72 and 81.3% below the Drug Manufacturers industry median of 11.41. Vext Science's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Vext Science (FRA:VV5), the current ROC (Joel Greenblatt) % is 2.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vext Science (FRA:VV5) Overvalued in 2026?
Based on GuruFocus' analysis, Vext Science stock appears to be undervalued.
The current stock price of €0.14 is trading 84.8% below its estimated GF Value™ of €0.94.
Key valuation signals for FRA:VV5:
ROC (Joel Greenblatt) %: 2.13% (88% below median its 10-year median of 17.72)
GF Value™: €0.94 vs. price of €0.14 (84.8% below fair value)
Industry Position: 81.3% below the Drug Manufacturers median (#784 of 982)
No single metric tells the full story. See the FRA:VV5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vext Science Inc engages in the full spectrum of the cannabis product lifecycle, from development and manufacturing to distribution. Its brands include Herbal Wellness, Appalachian Pharm, Revibe, Prism, Vapen, and Firebrand. In Arizona and Ohio, the dispensaries operate under the Herbal Wellness Center brand, while in Ohio the cultivation and manufacturing operations are licensed and branded as Appalachian Pharms Cultivation and Appalachian Pharm Processing. The Company operates through a single operating segment engaged in the cultivation, manufacturing, distribution, and sale of cannabis within the United States. All revenues are generated in the United States.
67GF Score
Get the complete analysis for FRA:VV5
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VV5 has been successfully added to your 
